2137 Stock Overview
Engages in the research and development of therapies for the treatment of infectious and central nervous system diseases in China and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Brii Biosciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.24 |
| 52 Week High | HK$5.92 |
| 52 Week Low | HK$1.21 |
| Beta | 1.77 |
| 11 Month Change | -26.19% |
| 3 Month Change | -50.40% |
| 1 Year Change | -78.21% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2137 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -32.2% | -6.4% | -1.0% |
| 1Y | -78.2% | -13.5% | 15.0% |
Return vs Industry: 2137 underperformed the Hong Kong Biotechs industry which returned -42.3% over the past year.
Return vs Market: 2137 underperformed the Hong Kong Market which returned -15.9% over the past year.
Price Volatility
| 2137 volatility | |
|---|---|
| 2137 Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.8% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 2137's share price has been volatile over the past 3 months.
Volatility Over Time: 2137's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 133 | Zhi Hong | www.briibio.com |
Brii Biosciences Limited engages in the research and development of therapies for the treatment of infectious and central nervous system diseases primarily in China and the United States. The company develops BRII-179, BRII-835, and BRII-877, which are in Phase 2 the development of a functional cure for HBV for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 2; and BRII-732 that is in Phase 1 clinical trail and BRII-753, which is in preclinical stage for the treatment of HIV. It also develops BRII-296 for the treatment of PPD/MDD, anxiety, and other depressive disorders; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for oral treatment for patients with chronic NTM lung disease.
Brii Biosciences Limited Fundamentals Summary
| 2137 fundamental statistics | |
|---|---|
| Market cap | HK$904.73m |
| Earnings (TTM) | -HK$355.03m |
| Revenue (TTM) | HK$146.18m |
5.1x
P/S Ratio-2.1x
P/E RatioIs 2137 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2137 income statement (TTM) | |
|---|---|
| Revenue | CN¥134.49m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥134.49m |
| Other Expenses | CN¥461.13m |
| Earnings | -CN¥326.64m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.45 |
| Gross Margin | 100.00% |
| Net Profit Margin | -242.87% |
| Debt/Equity Ratio | 0% |
How did 2137 perform over the long term?
See historical performance and comparison